Biorithm, a Singapore- and US-based company developing cutting-edge solutions for personalised connected maternity care, has secured US$3.5 million in Series A funding.
The round was co-led by Adaptive Capital Partners and SEEDS Capital.
The funding will be utilised to double down on expanding the reach of Biorithm’s connected pregnancy management solutions across Southeast Asia and the US. A portion of the capital will go into R&D.
Also Read: Revolutionising Singapore’s healthcare amidst demographic shifts and economic demands
The medtech firm will use the capital to fortify its US market entry and growth strategy and pursue breakthrough research.
Biorithm aims to end preventable pregnancy complications (which result in mortality for 800 women daily) through protocol-based remote monitoring of maternal and fetal biometrics.
Its Femom technology facilitates patient monitoring, accessibility of personalised guidance, and integration of predictive analytics that help clinicians identify early signs of complications.
“There is a collapse of maternal care driven by socio-economic factors and limitation of current monitoring technologies in many regions across the world, and we are hard at work to solve this problem in partnership with the wider health ecosystems at play,” said Amrish Nair, Founder and CEO, Biorithm.
Also Read: Decoding digital preferences: A glimpse into the future of health tech ecosystem in SEA
Having completed clinical trials with healthcare institutions in Singapore and the UK, Biorithm will expand its clinical trial footprint to more priority markets. To strengthen the women’s health ecosystem, it will chart out and foster key partnerships with various stakeholders globally to improve maternal and baby health through data and personalised and accessible care.
The post Biorithm scores US$3.5M for solution that prevents pregnancy complications appeared first on e27.